CN114222741B - 作为p2x3抑制剂的吡啶并嘧啶类衍生物 - Google Patents

作为p2x3抑制剂的吡啶并嘧啶类衍生物

Info

Publication number
CN114222741B
CN114222741B CN202080038831.1A CN202080038831A CN114222741B CN 114222741 B CN114222741 B CN 114222741B CN 202080038831 A CN202080038831 A CN 202080038831A CN 114222741 B CN114222741 B CN 114222741B
Authority
CN
China
Prior art keywords
pyrimidin
pyrido
amine
fluorophenyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080038831.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN114222741A (zh
Inventor
P·布鲁诺
M·比亚杰蒂
C·费奥莱里
C·贝克-格伦
H·范德波尔
S·D·派恩鲁斯
R·拉那罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Publication of CN114222741A publication Critical patent/CN114222741A/zh
Application granted granted Critical
Publication of CN114222741B publication Critical patent/CN114222741B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080038831.1A 2019-05-31 2020-05-28 作为p2x3抑制剂的吡啶并嘧啶类衍生物 Active CN114222741B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19177610 2019-05-31
EP19177610.3 2019-05-31
EP19201165.8 2019-10-02
EP19201165 2019-10-02
PCT/EP2020/064915 WO2020239953A1 (en) 2019-05-31 2020-05-28 Pyridopyrimidines derivatives as p2x3 inhibitors

Publications (2)

Publication Number Publication Date
CN114222741A CN114222741A (zh) 2022-03-22
CN114222741B true CN114222741B (zh) 2025-12-30

Family

ID=70857198

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080038831.1A Active CN114222741B (zh) 2019-05-31 2020-05-28 作为p2x3抑制剂的吡啶并嘧啶类衍生物

Country Status (11)

Country Link
US (1) US12606562B2 (https=)
EP (1) EP3976609A1 (https=)
JP (1) JP7797204B2 (https=)
KR (1) KR102923602B1 (https=)
CN (1) CN114222741B (https=)
AU (1) AU2020281924B2 (https=)
BR (1) BR112021020279A2 (https=)
CA (1) CA3136024A1 (https=)
MA (1) MA56020A (https=)
MX (1) MX2021014116A (https=)
WO (1) WO2020239953A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3139018A1 (en) 2019-05-31 2020-12-03 Chiesi Farmaceutici S.P.A. Amino quinazoline derivatives as p2x3 inhibitors
JP7797204B2 (ja) 2019-05-31 2026-01-13 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ｐ２ｘ３阻害剤としてのピリドピリミジン誘導体
WO2022160931A1 (zh) * 2021-01-28 2022-08-04 浙江海正药业股份有限公司 吡啶并嘧啶类衍生物及其制备方法和用途
AR132737A1 (es) 2023-05-22 2025-07-23 Chiesi Farm Spa Proceso e intermedios para la preparación de un inhibidor p2x3

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011041655A1 (en) * 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Quinazolin-4-amine derivatives; and methods of use
CN109641886A (zh) * 2015-11-25 2019-04-16 康威基内有限公司 双环bet布罗莫结构域抑制剂及其用途
CN112739699A (zh) * 2018-07-25 2021-04-30 费斯制药股份有限公司 作为组胺h4受体抑制剂的吡啶并嘧啶化合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH31122A (en) 1993-03-31 1998-02-23 Eisai Co Ltd Nitrogen-containing fused-heterocycle compounds.
JP4342007B2 (ja) * 1998-08-10 2009-10-14 大日本住友製薬株式会社 キナゾリン誘導体
CA2557372C (en) 2004-03-05 2013-01-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 antagonists
CN101300012B (zh) * 2005-09-01 2011-09-14 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物在制备治疗呼吸系统疾病的药物中的应用
MX2008014689A (es) 2006-05-23 2008-11-27 Hoffmann La Roche Derivados de piridopirimidininona.
EP2038264B1 (en) 2006-06-29 2016-10-26 F.Hoffmann-La Roche Ag Tetrazole-substituted arylamides
TW200840584A (en) 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
EP2136639B1 (en) 2007-04-02 2016-03-09 Evotec AG Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
PT2139334E (pt) 2007-04-17 2013-10-02 Evotec Ag Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos
CA2715835C (en) 2008-02-29 2017-03-21 Renovis, Inc. Amide compounds, compositions and uses thereof
JP5608655B2 (ja) 2008-09-18 2014-10-15 エヴォテック アーゲー Ｐ２ｘ３受容体活性のモジュレーター
BRPI0919488A2 (pt) 2008-09-30 2015-12-01 Astrazeneca Ab composto, uso de um composto, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto
PL2399910T3 (pl) 2009-02-13 2014-09-30 Shionogi & Co Pochodne triazyny jako antagoniści receptora p2x3 i/albo p2x2/3 i kompozycja farmaceutyczna zawierająca je
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
KR101685862B1 (ko) 2012-12-27 2016-12-20 에프. 호프만-라 로슈 아게 Comt 억제제
WO2016053794A1 (en) 2014-09-30 2016-04-07 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
JPWO2016084922A1 (ja) 2014-11-28 2017-09-07 塩野義製薬株式会社 １，２，４−トリアジン誘導体およびその医薬組成物
WO2016088838A1 (ja) 2014-12-04 2016-06-09 塩野義製薬株式会社 プリン誘導体およびその医薬組成物
EP3230281B1 (en) 2014-12-09 2021-05-26 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
WO2017011729A1 (en) 2015-07-16 2017-01-19 Patara Pharma, LLC Combination therapies for the treatment of lung diseases
DK3355889T3 (da) 2015-09-29 2023-05-15 Afferent Pharmaceuticals Inc Diaminopyrimidin-p2x3- og p2x2/3-receptormodulatorer til anvendelse i behandling af hoste
CN106565684B (zh) 2016-03-18 2019-06-18 南方医科大学 6-吡唑取代喹唑啉类化合物及其衍生物、合成方法及其应用
CA3029457A1 (en) 2016-06-30 2018-01-04 Gilead Sciences, Inc. 4,6-diaminoquinazolines as cot modulators and methods of use thereof
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
US11000491B2 (en) 2017-05-05 2021-05-11 Hepanova, Inc. Amino-aryl-benzamide compounds and methods of use thereof
CN109721554A (zh) 2019-01-08 2019-05-07 贵州大学 一类4-氨基喹唑啉类化合物及其制备方法和应用
JP7797204B2 (ja) 2019-05-31 2026-01-13 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ｐ２ｘ３阻害剤としてのピリドピリミジン誘導体
CA3139018A1 (en) 2019-05-31 2020-12-03 Chiesi Farmaceutici S.P.A. Amino quinazoline derivatives as p2x3 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011041655A1 (en) * 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Quinazolin-4-amine derivatives; and methods of use
CN109641886A (zh) * 2015-11-25 2019-04-16 康威基内有限公司 双环bet布罗莫结构域抑制剂及其用途
CN112739699A (zh) * 2018-07-25 2021-04-30 费斯制药股份有限公司 作为组胺h4受体抑制剂的吡啶并嘧啶化合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk);Bryan T. Mott等;《Bioorganic & Medicinal Chemistry Letters》;20091003;第19卷;第6700-6705页 *
Ju Hou等.Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.《European Journal of Medicinal Chemistry》.2016,第118卷第276-289页. *
Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk);Andrew S. Rosenthal等;《Bioorganic & Medicinal Chemistry Letters》;20110304;第21卷;第3152-3158页 *
RN2062039-46-5等化合物;ACS;《REGISTRY(STN)》;20170131;第1-5页 *

Also Published As

Publication number Publication date
JP2022534434A (ja) 2022-07-29
JP7797204B2 (ja) 2026-01-13
WO2020239953A1 (en) 2020-12-03
US20230212169A9 (en) 2023-07-06
US20220235060A1 (en) 2022-07-28
CN114222741A (zh) 2022-03-22
KR20220016074A (ko) 2022-02-08
US12606562B2 (en) 2026-04-21
MA56020A (fr) 2022-04-06
AU2020281924A1 (en) 2021-12-16
CA3136024A1 (en) 2020-12-03
AU2020281924B2 (en) 2026-04-16
MX2021014116A (es) 2021-12-10
EP3976609A1 (en) 2022-04-06
KR102923602B1 (ko) 2026-02-06
BR112021020279A2 (pt) 2021-12-14

Similar Documents

Publication Publication Date Title
CN114269432B (zh) 作为p2x3抑制剂的氨基喹唑啉衍生物
CN114222741B (zh) 作为p2x3抑制剂的吡啶并嘧啶类衍生物
EP4251617B1 (en) (aza)quinoline 4-amines derivatives as p2x3 inhibitors
EP4251273B1 (en) Phthalazine derivatives as p2x3 inhibitors
RU2833037C2 (ru) Производные пиридопиримидинов в качестве ингибиторов p2x3
HK40060820A (zh) 作为p2x3抑制剂的吡啶并嘧啶类衍生物
HK40091208A (zh) 作为p2x3抑制剂的酞嗪衍生物
HK40106991A (zh) 作为p2x3抑制剂的氨基喹唑啉衍生物
HK40062196B (zh) 作为p2x3抑制剂的氨基喹唑啉衍生物
HK40088660A (zh) 作为p2x3抑制剂的(氮杂)喹啉4-胺衍生物
HK40057265B (zh) 作为p2x3抑制剂的氨基喹唑啉衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40060820

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant